Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study tracks joint health in hemophilia a patients on prophylaxis

NCT ID NCT06684314

Disease control Sponsor: Sanofi Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study in Taiwan will follow about 100 people with moderate to severe hemophilia A who are already taking efanesoctocog alfa (a clotting factor) as part of their routine care. Researchers will track joint health, bleeding rates, and safety over up to 5 years using medical records and imaging. The goal is to see how well the medicine works in everyday life to protect joints and reduce bleeds.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
efanesoctocog alfa (a clotting factor medicine)
What this could lead to
If successful, this study could show that efanesoctocog alfa helps protect joints and reduce bleeding in people with hemophilia A in real-world use.
What could go wrong
This is an observational study, not a controlled trial, so results may be influenced by other factors. It is also small (100 participants) and limited to Taiwan, so findings may not apply broadly.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2024

Expected to finish

Aug 2031

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Participants from medical centers in Taiwan will be enrolled in the study after the introduction of efanesoctocog alfa for the treatment of hemophilia A. Eligible participants will include all ages, sexes and moderate to severe hemophilia A severities under efanesoctocog alfa prophylaxis treatment and able to undergo joint and/or MRI examinations during routine clinical practice.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participants with all ages and diagnosis of moderate-severe hemophilia A without current and/or at least three years of un-detectable inhibitor (\<0.6 BU) * Participants with moderate to severe hemophilia A as defined by FVIII level ≤ 5% * Participants starting efanesoctocog alfa prophylaxis treatment as per standard of care no more than three months prior to the enrollment date * Participants aged 6 years and older are able to undergo MRI examinations (sedation given, if necessary, and per investigator discretion) * Participants are able to undergo joint examinations * Physician's decision to treat the participant with efanesoctocog alfa is made prior to and independently of participation in the study * Signed and dated informed consent provided by the participant, or by the participant's legally acceptable representative for participants under the legal age before any study-related activities are undertaken. Assent should be obtained for pediatric participants according to local regulations Exclusion Criteria: * Participants with coagulation disorders other than hemophilia A * Participants diagnosed with other known bleeding disorder * Participants currently receive factor therapy and have signs of decreased response to FVIII therapy * Participants with a baseline Radiological Pettersson score (PS) of greater than 6 for each individual ankle * Enrollment in another concurrent clinical interventional study, or intake of an Investigational Medicinal Product within 3 months prior to inclusion in this study * Pregnant female participants The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hemophilia A are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

coagulation protein disease hemarthrosis hematologic disorder hemophilia A hemorrhagic disease hereditary disease inherited blood coagulation disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hemophilia A

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    10 sites. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Investigational Site Number : 1580001

    RECRUITING

    Taipei, 100, Taiwan

  • Investigational Site Number : 1580002

    RECRUITING

    Taipei, 114, Taiwan

  • Investigational Site Number : 1580003

    RECRUITING

    Taipei, 110, Taiwan

  • Investigational Site Number : 1580004

    RECRUITING

    Taoyuan City, 33305, Taiwan

  • Investigational Site Number : 1580005

    RECRUITING

    Taichung, 40201, Taiwan

  • Investigational Site Number : 1580006

    RECRUITING

    Taichung, 40447, Taiwan

  • Investigational Site Number : 1580007

    RECRUITING

    Taichung, 40705, Taiwan

  • Investigational Site Number : 1580008

    RECRUITING

    Changhua, 500, Taiwan

  • Investigational Site Number : 1580009

    RECRUITING

    Kaohsiung City, 807, Taiwan

  • Investigational Site Number : 1580010

    RECRUITING

    Kaohsiung City, 83301, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.